Can I read Ruxolitinib: a Potential Treatment for Corticosteroid Refractory Acute Graft-versus-host Disease on EtoBox?

Ruxolitinib: a Potential Treatment for Corticosteroid Refractory Acute Graft-versus-host Disease by Abedin, Sameem M.; Hamadani, Mehdi is a Medicine article available to read on EtoBox.

What is Ruxolitinib: a Potential Treatment for Corticosteroid Refractory Acute Graft-versus-host Disease about?

## Introduction: Allogeneic transplantation represents a potentially curative procedure for various lethal conditions; however, it is associated with serious immune mediated complications. the most serious complication is graft-versus-host disease (gvhd). acute gvhd (agvhd) is unresponsive to initial corticosteroid therapy in ~40% of cases. corticosteroid-refractory agvhd (cr-agvhd) represents a significant unmet need with nearly 60% mortality in patients developing this state. ## Areas covered: We review landmark trials which led to the us fda approval of ruxolitinb for the treatment of cr-agvhd. ruxolitinib phosphate is a janus kinase 1 and 2 inhibitor which inhibits pro-inflammatory signaling, and modulates t-cell subsets to an anti-inflammatory phenotype. ruxolitinib was recently prospectively studied for the treatment of cr-agvhd in the reach1 trial, which added ruxolitinib to corticosteroid therapy. this trial demonstrated favorable results with 73% of patients ultimately responding. among responders, over 70% remained alive at 6 months. these results led to the us fda to approve ruxolitinib as treatment for cr-agvhd, the first approval of its kind. ## Expert opinion: Ruxolit

Who reads Ruxolitinib: a Potential Treatment for Corticosteroid Refractory Acute Graft-versus-host Disease?

Author

Abedin, Sameem M.; Hamadani, Mehdi

Publisher

Informa plc; Informa UK (Taylor & Francis); Taylor & Francis; Informa UK Limited; Informa Healthcare (ISSN 1354-3784)

Published

2020

Language

EN

Field

Medicine (Health Sciences)